Opinion on Pharmaceuticals and Healthcare in North America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

"GreeneChip": new tool with broad use

A novel diagnostic tool, able to simultaneously screen for up to 30,000 different viruses, bacteria, fungi and parasites is currently being investigated by researchers at New York's Columbia University. Although its widespread availability requires more work, such a tool could help physicians give a more accurate diagnosis and prescribe appropriate treatment.

Published By Datamonitor
13 Dec 2006
Expert View
Expert View

"The pill" goes natural with potential new bestseller

Teva has announced the EU approval of NOMAC/E2, the first monophasic contraceptive with natural estrogen. The perceived increased safety of natural estrogen and a global launch will drive sales of the product, making it a leading hormonal contraceptive brand. To maximize its potential, however, Teva needs to show improved safety over synthetic estrogen contraceptives in post-marketing studies.

Published By Datamonitor
03 Aug 2011
Expert View
Expert View

'Conservative' pharmaceutical industry slow to take advantage of online marketing opportunities

While the internet has altered the landscape in the retail sector and revolutionized the airline industry, pharmaceutical companies have been slow to take advantage of the marketing opportunities offered by the medium. With existing sales and marketing strategies widely considered unsustainable, the industry needs to evolve and engage with its customers online, or it risks being left behind.

Published By Datamonitor
23 Apr 2008
Expert View
Expert View

A blockbuster is born in Johnson & Johnson's Nucynta ER

Johnson & Johnson has received FDA approval for Nucynta ER in moderate to severe chronic pain. Backed by clinical trial data showing comparable efficacy and superior tolerability to the market-leading opioid, OxyContin, Nucynta ER will be a commercial success for Johnson & Johnson. Additional benefits in neuropathic pain will further strengthen the clinical argument for its use.

Published By Datamonitor
30 Aug 2011
Expert View
Expert View

A European home for orphan drugs

Published By Datamonitor
15 Feb 2001
Expert View
Expert View

A Mars a day to keep the doctor away?

Mars has unveiled a new product range that claims to satisfy chocolate lovers' cravings while also being good for the heart. With obesity on the rise, and following clampdowns on junk food in US and European schools, entering the health foods market could be a good move. However, Mars is not the only one to realize this, meaning it could face stiff competition.

Published By Datamonitor
16 Sep 2005
Expert View
Expert View

A new phase in the breast cancer battle?

Published By Datamonitor
21 Sep 2001
Expert View
Expert View

A regulatory irony

Published By Datamonitor
22 Dec 2000
Expert View
Expert View

AAN 2010: late-stage pipeline candidates take center stage in migraine

In the wake of Imitrex's and Topamax's patent expiries, announcements at this year's American Academy of Neurology meeting focused firmly on the next major breakthroughs for the acute and prophylactic migraine markets. Pooled data for candidates from Allergan and Merck & Co demonstrated impressive potential, suggesting renewed hope for sufferers.

Published By Datamonitor
20 Apr 2010
Expert View
Expert View

AAN 2010: new treatments address unmet needs in Alzheimer's and epilepsy

A number of leading drug makers used this year's meeting of the American Academy of Neurology to present new data for promising pipeline candidates. Despite promising results, however, Datamonitor believes that the epilepsy drugs will struggle to find their place in the market. Moreover, the positive Phase II data for Baxter's potential Alzheimer's therapy Gammagard do not guarantee later success.

Published By Datamonitor
20 Apr 2010

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.